Hydroxamic Acid Derivatives for Potent, Selective Meprin Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors of meprin β and α lack potency, selectivity, and drug-like properties, and there is a need for effective treatments or prophylaxis of diseases associated with these enzymes, such as Alzheimer's disease, nephritis, renal injury, and inflammatory bowel disease.
Innovation Solution
Development of novel hydroxamic acid derivatives represented by Formula I, including enantiomers, diastereoisomers, hydrates, solvates, and pharmaceutically acceptable salts, which act as potent, selective, and dual inhibitors of meprin β and α, suitable for pharmaceutical compositions and therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current inhibitors of meprin β and α are used, then some inhibitory activity is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of hydroxamic acid derivatives through systematic variation of R1, R2, R3, R4 substituents and n values. This structural optimization enables the compounds to achieve both high potency (nanomolar IC50 values) and selectivity for meprin β and/or α, resolving the contradiction between achieving inhibitory activity and improving potency/selectivity.
2Object-affected harmful factors
If meprin β and α activity is inhibited, then disease progression is reduced, but lack of potent selective inhibitors limits therapeutic effectiveness
Solution Approach 1:
The patent employs composite material principles by creating hybrid molecules that combine the hydroxamic acid core structure with diverse aromatic and heterocyclic substituents. This composite molecular design produces compounds with optimized pharmacological properties including high potency, selectivity, and drug-like characteristics, thereby improving therapeutic effectiveness for treating meprin-related diseases.
3Adaptability or versatility
If broad-spectrum metalloprotease inhibitors are used, then meprin inhibition is achieved, but selectivity between meprin β and α is insufficient
Solution Approach 1:
The patent applies local quality principles by introducing specific substituent patterns at defined positions (R1, R2, R3, R4) on the hydroxamic acid core structure. These localized structural modifications create steric and electronic properties that confer selectivity for meprin β versus meprin α, allowing the compounds to differentiate between the two enzymes while maintaining inhibitory activity.
Data Source
AI summary
The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin β and/or α, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin β and/or α, and compounds and pharmaceutical compositions for use in such methods.